Trendlines Group Ltd. (SG:42T)
SGX:42T
Top Page
Trendlines Group
(SGX:42T)
Select Model
Select Model
Rating:50Neutral
Price Target:
S$0.06
▼(-22.50% Downside)
Action:ReiteratedDate:01/08/26
The score is held down primarily by weak financial performance (negative profitability and negative operating/free cash flow), partially offset by strong technical momentum (price above key moving averages and positive MACD). Valuation is constrained by a negative P/E tied to losses and the lack of a dividend yield.
Positive Factors
Focused incubator/venture model
Trendlines’ specialized incubator model in medtech and agrifood creates durable competitive advantage: deep domain expertise, access to academic technologies, and bundled support (regulatory, clinical, commercialization) increase portfolio success chances and drive long-term value realization through exits or licenses.
Negative Factors
Weak revenue and profitability trends
Sustained negative revenue and margins impair the company’s ability to self-fund operations and demonstrate product/portfolio traction. Continued top-line decline reduces reinvestment capacity, weakens return on equity, and increases reliance on external capital or asset monetization for growth and working capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused incubator/venture model
Trendlines’ specialized incubator model in medtech and agrifood creates durable competitive advantage: deep domain expertise, access to academic technologies, and bundled support (regulatory, clinical, commercialization) increase portfolio success chances and drive long-term value realization through exits or licenses.
Read all positive factors
Trendlines Group (42T) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$80.05M
Dividend YieldN/A
Average Volume (3M)9.96M
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth-41.81%
EPS Growth66.47%
CountrySG
Employees23
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,455,493,500
10 Day Avg. Volume4,639,890
30 Day Avg. Volume9,962,306
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.56
Price to Sales (P/S)22.29
P/FCF Ratio-4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Trendlines Group Business Overview & Revenue Model
Company Description
The Trendlines Group Ltd. is an innovation commercialization company and a private equity and venture capital firm specializing in incubation, seed, start-up, early venture and late venture investments. The firm seeks to invest in food, medtech, c...
How the Company Makes Money
Trendlines Group generates revenue primarily through its investments in early-stage companies. The company earns money by taking equity stakes in these businesses and benefiting from their growth and exit events, such as acquisitions or public off...
Trendlines Group Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -8.32M | 1.72M | 4.50M | 3.58M | 2.30M | -3.76M |
| Gross Profit | -19.53M | -1.73M | -793.00K | -3.83M | -5.04M | -15.68M |
| EBITDA | -19.34M | -9.28M | -33.93M | -16.39M | 3.95M | -14.98M |
| Net Income | -18.87M | -9.43M | -33.99M | -14.48M | 6.56M | -4.93M |
Balance Sheet | ||||||
| Total Assets | 73.26M | 75.35M | 78.07M | 107.99M | 121.08M | 154.32M |
| Cash, Cash Equivalents and Short-Term Investments | 2.89M | 5.89M | 6.11M | 6.57M | 18.46M | 14.07M |
| Total Debt | 5.45M | 4.15M | 4.64M | 4.85M | 10.01M | 7.39M |
| Total Liabilities | 8.63M | 7.32M | 9.00M | 12.10M | 18.54M | 27.09M |
| Stockholders Equity | 65.47M | 68.55M | 70.89M | 96.99M | 103.09M | 127.21M |
Cash Flow | ||||||
| Free Cash Flow | -9.84M | -8.86M | -6.42M | -15.04M | 76.00K | -4.50M |
| Operating Cash Flow | -9.80M | -8.84M | -6.34M | -14.93M | 650.00K | -3.86M |
| Investing Cash Flow | -200.93K | -948.00K | 1.92M | 2.05M | -598.00K | -5.83M |
| Financing Cash Flow | 5.26M | 8.64M | 5.97M | 3.13M | 3.60M | -490.00K |
Trendlines Group Technical Analysis
Positive
0.08
Price Trends
0.06
Negative
0.06
Negative
0.05
Positive
Market Momentum
>-0.01
Negative
53.61
Neutral
81.72
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42T, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.61 is Neutral, neither overbought nor oversold. The STOCH value of 81.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:42T.
Trendlines Group Peers Comparison
UnderperformOutperform
Sector (68)
SG:42T
Trendlines Group
0.06
0.02
60.00%
SG:BLS
Hotung Investment Holdings Limited
1.41
0.12
9.30%
SG:I49
IFS Capital Ltd.
0.22
0.10
78.86%
SG:S23
Singapura Finance Ltd
0.81
0.17
26.37%
SG:S35
Sing Investments & Finance Limited
1.54
0.46
42.59%
SG:T55
TIH Limited
0.20
<0.01
2.05%
Trendlines Group Corporate Events
Trendlines Bolsters Capital Base and Portfolio Momentum With New Placements and Leadership Moves
Feb 3, 2026
Trendlines Group has undertaken a series of corporate actions over December 2025 and January 2026 to strengthen its capital base and streamline its operations, including the successful subscription and placement of significant tranches of new ordi...
Trendlines Finalises Transfer of Agrifood Fund Management to Proterra
Jan 29, 2026
Trendlines has completed the previously announced transfer of management of its Trendlines Agrifood Fund Pte. Ltd. to Proterra Investment Advisors (Singapore) Pte. Ltd., after securing unanimous investor consent and fulfilling all regulatory and a...
Trendlines Group Completes S$0.067 Share Placement, Expanding Equity Base
Jan 15, 2026
Trendlines Group Ltd. has completed a private placement of 83,680,000 new ordinary shares at S$0.067 per share, increasing its issued and paid-up share capital from 1,371,813,553 to 1,455,493,553 shares. The new shares, representing about 5.75% of...
Trendlines Group Wins SGX Nod for Placement of Up to 83.68 Million New Shares
Jan 14, 2026
Trendlines Group has received in-principle approval from the Singapore Exchange (SGX-ST) for the listing and quotation of up to 83,680,000 new ordinary shares on the Catalist board at a placement price of S$0.067 per share, marking a key step in i...
Trendlines Group Plans S$5.6 Million Private Placement to Fund Portfolio Growth
Jan 8, 2026
Trendlines Group has launched a proposed private placement to raise S$5.6 million by issuing new shares representing roughly 5.75% of its enlarged share capital to a group of institutional and accredited investors, including clients managed by Lio...
Trendlines Group Launches S$5.6 Million Share Placement at Discount
Jan 7, 2026
Trendlines Group Ltd. has entered into a placement agreement with SAC Capital Private Limited, with Maybank Securities Pte. Ltd. acting as sub-placement agent, to place up to 83.68 million new ordinary shares at S$0.067 per share, raising up to S$...
Trendlines’ Portfolio Firm Limaca Strikes Exclusive U.S. Distribution Deal for Precision-GI Biopsy System
Jan 4, 2026
Trendlines Group announced that its portfolio company Limaca Medical has signed an exclusive U.S. distribution agreement with a global leader in endoscopy equipment for Limaca’s Precision-GI™ automated biopsy system. The deal is expect...
Trendlines Group Appoints New Joint Company Secretary
Dec 30, 2025
The Trendlines Group Ltd. has appointed Ms. Lee Sock Wei as Joint Company Secretary with effect from 1 January 2026, joining existing Company Secretary Ms. Sahar Farah. The board-level corporate secretarial change underscores the company’s c...
Trendlines Group Completes Share Subscription, Corrects Minor Disclosure Error
Dec 29, 2025
Trendlines Group Ltd., incorporated in Israel and listed on the Singapore Exchange Catalist board, has completed a share subscription exercise that bolsters its issued and paid-up share capital. The company allotted and issued 51,447,751 new ordin...
Trendlines Group Wins SGX Nod for Listing of 51.4 Million New Shares
Dec 29, 2025
Trendlines Group has received listing and quotation approval from the Singapore Exchange’s Catalist board for up to 51,447,751 new ordinary shares to be issued at S$0.0666 per share under a proposed subscription. The approval, which is condi...
Trendlines Group Transfers Management of Agrifood Fund to Proterra
Dec 11, 2025
Trendlines Group Ltd. has announced a management transfer agreement where Proterra Investment Advisors will become the sole investment manager of the Trendlines Agrifood Fund. This move aligns with Trendlines’ strategy to streamline operatio...
Trendlines Group Announces New Share Subscription Agreement
Dec 9, 2025
Trendlines Group Ltd. has announced a subscription agreement for the issuance of up to 51,447,751 new ordinary shares at a price of S$0.0666 per share, totaling approximately S$3,426,420. This move, which is not underwritten and involves no placem...
Trendlines Group Highlights Key Developments and Investor Engagements
Dec 1, 2025
Trendlines Group Ltd. has announced several key developments, including the successful completion of a $10 million Series A funding round by its portfolio company, IBI Ag Ltd. Additionally, Trendlines is actively engaging with investors and the pu...
Trendlines Group’s IBI Ag Secures $10 Million for Bioinsecticide Innovation
Nov 12, 2025
Trendlines Group’s portfolio company, IBI Ag, has successfully raised $10 million in a Series A funding round led by Corteva, marking a significant milestone in the development of its nanobody-based bioinsecticide platform. This investment w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.